392: Epstein's pal attempts a biotech comeback, and Prasad exits the FDA
About this episode
The episode discusses Boris Nikolic's new biotech investment firm and Vinay Prasad's exit from the FDA, along with other biotech news.
How was a known friend of Jeffrey Epstein able to raise $100 million, with the help of a prominent biotech VC? And will Vinay Prasad return to the Food and Drug Administration for a "three-peat"? Damian Garde joins Allison, Adam, and Elaine to discuss his article about Boris Nikolic, a well-connected biotech investor with deep ties to Jeffrey Epstein, who has raised a new biotech investment firm. The hosts also talk about Prasad's second exit from the FDA and a congressman's probing of the agency's rare disease drug denials. And they recap Novo Nordisk and Hims' detente and Xenon Pharmaceuticals' promising seizure data.
People in this episode
Hosts: Allison, Adam, Elaine
Guest: Damian Garde
Topics covered
- biotech investment
- FDA
- rare diseases
- drug approvals
- biotech comeback
- Epstein connections
Keywords
- biotech
- FDA
- Vinay Prasad
- Boris Nikolic
- drug approvals
- Novo Nordisk
- Hims
- Xenon Pharmaceuticals
- rare diseases
Mentioned in this episode
Organizations: FDA, Novo Nordisk, Hims, Xenon Pharmaceuticals
More episodes of The Readout Loud
- 398: A CAR-T biotech's dramatic turnaround, and drugmakers' tactics to drive more scripts
- 397: A pancreatic cancer breakthrough, and new hope for an off-the-shelf CAR-T treatment
- 396: A new trick for old science, and biotech VCs' scrambled playbook
- 395: Biotech investors' plea to Trump, and a busy M&A week
- 394: Eli Lilly's deal man, Allogene's off-the-shelf CAR-T, and Merck's Terns buy
- 393: A conversation with the 'godfather' of biotech
Explore listener stats, chart rankings, contacts and more on the The Readout Loud podcast page.